Virtu Financial’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,634
| Closed | -$3.41M | – | 2302 |
|
|
2026
Q1 | $3.41M | Buy |
7,634
+6,141
| +411% | +$2.86M | 0.14% | 84 |
|
|
2025
Q4 | $676K | Buy |
+1,493
| New | +$644K | 0.03% | 479 |
|
|
2025
Q2 | – | Sell |
-9,064
| Closed | -$4.39M | – | 2072 |
|
|
2025
Q1 | $4.39M | Buy |
9,064
+1,543
| +21% | +$719K | 0.24% | 45 |
|
|
2024
Q4 | $3.03M | Buy |
7,521
+2,839
| +61% | +$1.32M | 0.16% | 110 |
|
|
2024
Q3 | $2.18M | Sell |
4,682
-9,705
| -67% | -$4.66M | 0.12% | 131 |
|
|
2024
Q2 | $6.74M | Buy |
+14,387
| New | +$6.24M | 0.47% | 28 |
|
|
2023
Q1 | – | Sell |
-6,486
| Closed | -$1.87M | – | 2144 |
|
|
2022
Q4 | $1.87M | Buy |
+6,486
| New | +$1.98M | 0.25% | 67 |
|
|
2021
Q4 | – | Sell |
-6,887
| Closed | -$1.25M | – | 2213 |
|
|
2021
Q3 | $1.25M | Buy |
+6,887
| New | +$1.34M | 0.11% | 178 |
|
|
2020
Q3 | – | Sell |
-1,050
| Closed | -$305K | – | 1558 |
|
|
2020
Q2 | $305K | Buy |
+1,050
| New | +$285K | 0.04% | 543 |
|
|
2019
Q4 | $638K | Buy |
2,912
+777
| +36% | +$157K | 0.06% | 339 |
|
|
2019
Q3 | $362K | Buy |
+2,135
| New | +$378K | 0.03% | 642 |
|
|
2019
Q2 | – | Sell |
-8,533
| Closed | -$1.57M | – | 1914 |
|
|
2019
Q1 | $1.57M | Buy |
+8,533
| New | +$1.58M | 0.09% | 194 |
|
|
2018
Q3 | – | Sell |
-8,168
| Closed | -$1.39M | – | 2259 |
|
|
2018
Q2 | $1.39M | Buy |
8,168
+6,551
| +405% | +$1.02M | 0.08% | 259 |
|
|
2018
Q1 | $264K | Buy |
+1,617
| New | +$264K | 0.01% | 1151 |
|
|
2017
Q4 | – | Sell |
-19,372
| Closed | -$2.94M | – | 3070 |
|
|
2017
Q3 | $2.94M | Buy |
+19,372
| New | +$2.92M | 0.15% | 90 |
|
|
2016
Q4 | – | Sell |
-3,331
| Closed | -$290K | – | 577 |
|
|
2016
Q3 | $290K | Buy |
+3,331
| New | +$315K | 0.05% | 279 |
|
|
2016
Q1 | – | Sell |
-3,839
| Closed | -$483K | – | 521 |
|
|
2015
Q4 | $483K | Buy |
+3,839
| New | +$463K | 0.07% | 237 |
|
|
2015
Q3 | – | Sell |
-4,457
| Closed | -$550K | – | 407 |
|
|
2015
Q2 | $550K | Buy |
+4,457
| New | +$562K | 0.05% | 195 |
|
|
2014
Q4 | – | Sell |
-2,907
| Closed | -$326K | – | 405 |
|
|
2014
Q3 | $326K | Buy |
+2,907
| New | +$277K | 0.03% | 218 |
|
|
2014
Q2 | – | Sell |
-4,659
| Closed | -$329K | – | 462 |
|
|
2014
Q1 | $329K | Buy |
4,659
+1,528
| +49% | +$121K | 0.05% | 271 |
|
|
2013
Q4 | $233K | Buy |
+3,131
| New | +$218K | 0.02% | 228 |
|
Other funds holding VRTX
Virtu Financial's VRTX Position: Q2 2026 in Review
Virtu Financial sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 7,634 shares — an estimated $3.41M sold.
Virtu Financial first reported a position in VRTX in Q4 2013 and held it in 21 quarters. The position peaked at $6.74M in Q2 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Virtu Financial reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Virtu Financial sold 7,634 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.41M.
- Virtu Financial first reported a position in Vertex Pharmaceuticals in Q4 2013 and held it in 21 quarters.
- Virtu Financial's Vertex Pharmaceuticals position peaked at $6.74M in Q2 2024.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.